IM Cannabis Future Growth
Future criteria checks 2/6
IM Cannabis is forecast to grow earnings and revenue by 55% and 22.8% per annum respectively.
Key information
55.0%
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 23.8% |
| Revenue growth rate | 22.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 15 Aug 2024 |
Recent future growth updates
Recent updates
IM Cannabis Shareholder Rafael Gabay raises stake
Sep 08IM Cannabis GAAP EPS of -C$0.30, revenue of C$23.8M
Aug 15IM Cannabis receives non-compliance notification from Nasdaq for minimum bid price requirement
Jul 19cbdMD And IM Cannabis Partner To Sell CBD Products In Israeli Markets
Aug 14IM Cannabis proposes public offering of securities
May 05IM Cannabis acquires Israel's largest retail and online pharmacy business from Panaxia
Apr 30Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 71 | -5 | N/A | N/A | 2 |
| 12/31/2024 | 59 | -16 | N/A | N/A | 2 |
| 6/30/2024 | 50 | -14 | 5 | 6 | N/A |
| 3/31/2024 | 48 | -15 | -3 | -3 | N/A |
| 12/31/2023 | 49 | -9 | -9 | -8 | N/A |
| 9/30/2023 | 53 | -15 | -11 | -10 | N/A |
| 6/30/2023 | 54 | -17 | -16 | -15 | N/A |
| 3/31/2023 | 54 | -17 | -11 | -9 | N/A |
| 12/31/2022 | 54 | -23 | -14 | -13 | N/A |
| 9/30/2022 | 50 | -22 | -8 | -5 | N/A |
| 6/30/2022 | 44 | -16 | -26 | -22 | N/A |
| 3/31/2022 | 38 | -10 | -40 | -36 | N/A |
| 12/31/2021 | 34 | 0 | -39 | -34 | N/A |
| 9/30/2021 | 29 | -10 | -44 | -40 | N/A |
| 6/30/2021 | 27 | -12 | -29 | -26 | N/A |
| 3/31/2021 | 23 | -24 | -16 | -14 | N/A |
| 12/31/2020 | 16 | -29 | -11 | -8 | N/A |
| 9/30/2020 | 13 | -7 | -13 | -10 | N/A |
| 6/30/2020 | 10 | -10 | -12 | -9 | N/A |
| 3/31/2020 | 8 | -1 | -9 | -7 | N/A |
| 12/31/2019 | 9 | -7 | -8 | -6 | N/A |
| 9/30/2019 | 8 | -8 | -5 | -4 | N/A |
| 6/30/2019 | 7 | -6 | -4 | -3 | N/A |
| 3/31/2019 | 6 | -6 | -2 | -2 | N/A |
| 12/31/2018 | 5 | 2 | -1 | 0 | N/A |
| 12/31/2017 | 4 | 1 | N/A | 1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMCC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMCC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMCC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMCC's revenue (22.8% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: IMCC's revenue (22.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IMCC's Return on Equity is forecast to be high in 3 years time